Ergothioneine: The 'Longevity Vitamin' Candidate With a Dedicated Human Transporter

What Is Ergothioneine?

Ergothioneine (EGT) is a naturally occurring amino acid and antioxidant synthesized exclusively by fungi, mycobacteria, and a small number of actinobacteria — humans cannot produce it endogenously. Despite this, the human body expresses a dedicated high-affinity transporter for ergothioneine (OCTN2, gene SLC22A4), suggesting evolutionary pressure to accumulate and retain this compound. This transporter is expressed most densely in tissues under high oxidative stress: mitochondria-rich cells, erythrocytes, liver, kidney, bone marrow, and the brain.

After dietary intake (primarily from mushrooms and, to a lesser extent, black beans and oat bran), ergothioneine concentrates in tissues over weeks, with whole-blood concentrations in the low micromolar range. Its unusual stability — it is not readily oxidized under physiological conditions and can be recycled back to its reduced thione form — distinguishes it from most other dietary antioxidants.

The compound has attracted longevity research attention for three reasons: (1) species with longer lifespans appear to accumulate more ergothioneine, (2) plasma EGT concentrations decline with age in humans, and (3) epidemiological data have associated higher plasma levels with lower all-cause mortality.

Molecular Profile

Mechanism of Action

Thione Redox Chemistry

Ergothioneine exists primarily in its thione form (C=S) at physiological pH, rather than the thiol form (–SH) common to other sulfur-containing antioxidants. This tautomer is unusually stable and confers different reactivity: EGT scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS), including hydroxyl radicals, peroxynitrite, and hypochlorous acid, without the reactivity-driven instability that limits glutathione in some compartments.

Mitochondrial Concentration

OCTN2 is expressed on the inner mitochondrial membrane, enabling active concentration of EGT inside mitochondria — a key site of ROS generation. Animal studies demonstrate that EGT accumulation correlates with reduced mitochondrial oxidative damage markers, including 8-OHdG and lipid peroxidation products.

Metal Chelation

EGT chelates divalent metal ions, including Fe²⁺, Cu²⁺, Zn²⁺, and Mn²⁺. By sequestering redox-active metals, it can suppress Fenton-type reactions that generate hydroxyl radicals from hydrogen peroxide. This mechanism may be particularly relevant in iron-rich environments such as erythrocytes.

Cytoprotection Via OCTN2-Mediated Signaling

Beyond its direct antioxidant activity, activation of OCTN2 has been linked to downstream cytoprotective signaling, including Nrf2 pathway modulation and reduced inflammatory cytokine output (IL-6, TNF-α) in cell culture models. Whether this is mediated by EGT itself or by transporter activation remains under investigation.

What the Research Actually Shows

Animal Longevity Studies

The most striking data come from model organisms. A 2020 study published in Marine Drugs found that supplementing the nematode C. elegans with ergothioneine extended mean lifespan by approximately 30% at the highest tested doses, with improved resistance to thermal and oxidative stress. The effect depended on the C. elegans OCTN2 ortholog, suggesting transporter-mediated accumulation is necessary.

In Drosophila melanogaster, EGT supplementation extended median lifespan by 14–17% and improved locomotor activity in aged flies, with effects attenuating in oxidative-stress-pathway mutants.

Mouse studies are more limited. A 2021 paper in GeroScience reported that EGT supplementation in aged mice (18 months) reduced hippocampal oxidative stress markers and improved performance on spatial memory tasks (Morris water maze), but did not report lifespan data.

Limitation: These model organism results are not directly translatable to humans. Invertebrate lifespan extension frequently fails to replicate in rodents or primates.

Human Epidemiological Data

Two notable observational studies have examined plasma EGT in humans:

Singapore Chinese Health Study (2023, Nutrients): In 3,236 adults followed for approximately 20 years, higher tertile plasma EGT at baseline was associated with a 28% lower risk of all-cause mortality (HR 0.72; 95% CI 0.59–0.88) after adjusting for age, sex, BMI, smoking, alcohol, and dietary pattern. The association was attenuated but remained significant after adjustment for overall dietary quality scores, suggesting it was not purely a proxy for mushroom consumption.

NUS-COR Cohort (2021, Redox Biology): In 222 older Singaporean adults, plasma EGT correlated inversely with multiple cognitive decline biomarkers. Those in the lowest EGT quartile had significantly higher odds of mild cognitive impairment (OR 2.4; 95% CI 1.2–4.8).

Critical caveat: These are observational studies. Low plasma EGT could be a marker of low mushroom intake, poor gut absorption, or general frailty — any of which might independently predict mortality. Causality cannot be inferred.

Cognitive Research

Animal data on cognition are generally positive. EGT supplementation in rodent aging models consistently reduces hippocampal oxidative stress and inflammation markers. Two small human observational studies (one Singapore-based, one Japanese) have reported associations between higher mushroom consumption (the primary EGT source) and lower dementia incidence. A 2019 study in Journal of Alzheimer's Disease found a 57% reduced odds of mild cognitive impairment in adults consuming >2 portions/week of mushrooms vs. <1 portion/week (n=663), though mushrooms contain many bioactive compounds beyond EGT.

No completed randomized controlled trials have examined EGT supplementation for cognitive outcomes in humans as of mid-2026.

Cardiovascular and Metabolic

Limited cell culture and animal data suggest EGT reduces endothelial ROS production and LDL oxidation. A 2020 rodent study found that EGT supplementation reduced atherosclerotic plaque area in ApoE-knockout mice on a high-fat diet. Human trial data are absent.

Neuroprotection: Parkinson's Relevance

A Japanese case-control study (n=418) found significantly lower plasma EGT in Parkinson's disease patients vs. age-matched controls. OCTN2 is highly expressed in substantia nigra neurons, which are selectively vulnerable in PD. Whether this is cause, consequence, or confound is unknown.

Comparison to Other Longevity-Relevant Antioxidants

Ergothioneine is unusual in having a dedicated tissue-accumulating transporter, long biological half-life, and stability in its reduced form — properties that distinguish it from most dietary antioxidants and may support its relevance as a genuine micronutrient.

Research Limitations

Observational bias: The strongest human evidence (mortality and cognitive associations) comes from epidemiological data. Plasma EGT likely correlates with mushroom intake, dietary quality, and socioeconomic factors — all independent predictors of outcomes.

No completed RCTs for lifespan or cognition: As of mid-2026, no randomized controlled trial has examined EGT supplementation effects on longevity outcomes, cognitive decline, or cardiovascular disease in humans.

Dose-response unknown: Most human studies examine plasma levels as a marker, not as a function of supplemental dose. Effective supplemental doses in humans have not been established. Typical oral supplement doses range from 5 mg to 30 mg/day; bioavailability studies are limited.

Bioavailability variability: OCTN2 expression varies by SLC22A4 gene variant. Several common SNPs (notably the 503F variant) reduce transporter activity, potentially affecting EGT accumulation. Population-level studies rarely account for this.

Species gap: The 30% lifespan extension in C. elegans is not predictive of human effects. Invertebrate longevity interventions frequently fail to translate.

Key Takeaways

1. Ergothioneine is the only known dietary compound for which humans express a dedicated high-affinity transporter, suggesting it was retained evolutionarily as a functional micronutrient.
2. Animal model data consistently show lifespan extension and neuroprotection at supplemented doses, with effects dependent on OCTN2-mediated accumulation.
3. Human observational data associate higher plasma EGT with reduced all-cause mortality and lower cognitive impairment risk — but no interventional trials have confirmed causation.
4. Plasma EGT declines with age in humans, mirroring the trajectory seen with NAD+ and other longevity-associated metabolites.
5. Dietary sources (primarily mushrooms) provide typical intakes of 1–5 mg/day; supplement doses under study range from 5–30 mg/day.
6. The research case for EGT is intriguing and mechanistically coherent, but remains substantially below the evidence threshold of established interventions. It warrants monitoring as trials progress.

This article is for informational and research reference purposes only. Ergothioneine is sold as a dietary supplement in some jurisdictions but is not approved as a therapeutic agent for any condition. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to your supplement regimen.